InvestorsHub Logo
Followers 48
Posts 4545
Boards Moderated 0
Alias Born 10/26/2016

Re: None

Saturday, 09/30/2017 6:59:35 PM

Saturday, September 30, 2017 6:59:35 PM

Post# of 932
Am I reading this right?? How do you do Clinical Trial P1 in Mid 2018 and you anticipated running out of fund in the middle of 2018??


As a result of the workforce restructuring, which is anticipated to be completed by the end of the third quarter, Genocea estimates annualized savings of approximately $6.5 million in personnel-related costs, with estimated one-time severance and related costs of approximately $1.1 million in the third quarter of 2017. Genocea now expects that its existing cash and cash equivalents are sufficient to support its operating expenses and capital expenditure requirements into the middle of 2018.

The company plans to initiate a Phase 1 clinical trial for GEN-009 in a range of tumor types in the first half of 2018 and expects to report initial immunogenicity data in the first half of 2019.